Search Result "SN-38."
A Nanostructured Silica-Lipid Hybrid to Facilitate Oral SN-38-based Chemotherapy
Journal: Drug Delivery Letters
Volume: 6 Issue: 1 Year: 2016 Page: 11-17
Author(s): Thilagavathi Yuvaraj,Shasha Rao,Tri-Hung Nguyen,Ben J. Boyd,Clive A. Prestidge
P-Glycoprotein, but not Multidrug Resistance Protein 4, Plays a Role in the Systemic Clearance of Irinotecan and SN-38 in Mice
Journal: Drug Metabolism Letters
Volume: 4 Issue: 4 Year: 2010 Page: 195-201
Author(s): Michael Tagen, Yanli Zhuang, Fan Zhang, K. Elaine Harstead, Jun Shen, Paula Schaiquevich, Charles H. Fraga, John C. Panetta, Christopher M. Waters, Clinton F. Stewart
Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK
Journal: Recent Patents on Anti-Cancer Drug Discovery
Volume: 14 Issue: 2 Year: 2019 Page: 177-186
Author(s): Yingfang Fan,Najia Mansoor,Tasneem Ahmad,Zhuo X. Wu,Rafeeq A. Khan,Martin Czejka,Syed Sharib,Mansoor Ahmed,Zhe S. Chen,Dong H. Yang
CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity forCEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells
Journal: Current Cancer Drug Targets
Volume: 24 Issue: 7 Year: 2024 Page: 720-732
Author(s): Kelly C. Arias Cardenas,Clinton W. Enos,Mark R. Spear,Dana E. Austin
PEO-PPO-PEO/Poly(DL-lactide-co-caprolactone) Nanoparticles as Carriers for SN-38: Design, Optimization and Nano-Bio Interface Interactions
Journal: Current Drug Delivery
Volume: 13 Issue: 3 Year: 2016 Page: 339-352
Author(s): Rozafa Koliqi,Simona Dimchevska,Nikola Geskovski,Gjorgji Petruševski,Marina Chacorovska,Biljana Pejova,Delyan R. Hristov,Sonja Ugarkovic,Katerina Goracinova
Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecanâs Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea
Journal: Current Cancer Drug Targets
Volume: 19 Issue: 7 Year: 2019 Page: 551-560
Author(s): Rongjin Sun,Sumit Basu,Min Zeng,Robin Sunsong,Li Li,Romi Ghose,Wei Wang,Zhongqiu Liu,Ming Hu,Song Gao
CD44-Targeting for Antitumor Drug Delivery: A New SN-38-Hyaluronan Bioconjugate for Locoregional Treatment of Peritoneal Carcinomatosis
Journal: Current Cancer Drug Targets
Volume: 11 Issue: 5 Year: 2011 Page: 572-585
Author(s): A. Serafino, M. Zonfrillo, F. Andreola, R. Psaila, L. Mercuri, N. Moroni, D. Renier, M. Campisi, C. Secchieri, P. Pierimarchi
Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide
Journal: Current Drug Metabolism
Volume: 7 Issue: 4 Year: 2006 Page: 431-454
Author(s): Xiao-Xia Yang, Ze-Ping Hu, Sui Y. Chan, Wei Duan, Paul C.-L. Ho, Urs A. Boelsterli, Ka-Yun Ng, Eli Chan, Jin-Song Bian, Yu-Zong Chen, Min Huang, > Zhou
Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity
Journal: Current Medicinal Chemistry
Volume: 26 Issue: 12 Year: 2019 Page: 2085-2107
Author(s): Roberta Zilles Hahn,Marina Venzon Antunes,Simone Gasparin Verza,Magda Susana Perassolo,Edna Sayuri Suyenaga,Gilberto Schwartsmann,Rafael Linden
Effective Prodrug Liposome and Conversion to Active Metabolite
Journal: Current Drug Metabolism
Volume: 1 Issue: 1 Year: 2000 Page: 31-48
Author(s): Y. Sadzuka